India Pharmaceutical Market reports revenue decline in March 2022
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
The company is now introducing the product into the India pharmaceutical market.
Subscribe To Our Newsletter & Stay Updated